+972548034532 info@resultmed.com


Oncology news




Immunotherapy for lymphoma in Israel. (24/04/2020)
Immunotherapy for pancreatic cancer in Israel. (23/04/2020)
Immunotherapy for stomach (gastric) cancer in Israel. (22/04/2020)
Immunotherapy for sarcomas treatment in Israel. (21/04/2020)

Immunotherapy for liver cancer in Israel. (20/04/2020)

Immunotherapy for prostate cancer in Israel. (19/04/2020)

Tazemetostat was approved by FDA for the treatment of epithelioid sarcoma. (04/02/2020)

FoundationOne CDx Ovarian Cancer testing checks an effectiveness of Lynparza targeted therapy. (11/09/2019)

A family history of melanoma increases your risk of skin cancer by up to 74%. (22/08/2019)

Molecular testing for prostate cancer in Israel. (30/07/2019)

Onco tests for Thyroid Cancer in Israel. (23/07/2019)

Review – Oncotests used in Israel. (24/06/2019)

Medullary thyroid cancer. Rare type of cancer treatment in Israel. (09/06/2019)

Oncotest Teva Guardant 360 Liquid Biopsy – mutations test for all cancer types by blood analysis. (22/05/2019)

CAR-T therapy in Israel: treatment of multiple myeloma, acute leukemia and lymphoma has become more accessible. (29/04/2019)

Praluent (alirocumab) reduces mortality for atherosclerotic cardiovascular diseases (ASCVD). (23/04/2019)

Precancerous conditions and lesions – diagnostics and treatment in Israel. (17/04/2019)

Atezolizumab as a first line treatment for triple negative breast cancer. (13/03/2019)

♦ Resume – the latest achievements and successful cancer treatment strategies in Israel and the world in 2018. (21/02/2019)

♦ mFOLFIRINOX – significant survival increase in pancreatic carcinoma treatment. (05/02/2019)

♦ Test for tuberculosis (TB) before surgery in Israel – new requirements of Israeli clinics. (27/01/2019)

♦ Papillary carcinoma of the thyroid (PTC) treatment in Israel. (24/01/2019)

♦ LDH analysis for melanoma treatment prognosis – study. (21/01/2019)

♦ Non Small Cell Lung Cancer (NSCLC) – modern treatment methods in Israel. (15/12/2018)

♦ New vaccinations requirements before treatment in Israel. (15/11/2018)

Oncogenetic counseling in Israel. Gene mutation detection and treatment.  (06/03/2018)

Last stage cancer treatment in Israel. (06/02/2018)

♦ Triple Test Paradigm for precision cancer treatment in Israel. (08/01/2018)

♦  Personalized Cancer Prescreening in Israel – Creation of the Navigator Map of all potential treatment options, personally for each patient and his disease, outside of standard treatments. (03/01/2018)
♦ What is the difference between genetic and genomic testing? (01/01/2018)

Immunotherapy for breast cancer in Israel. (26/12/2017)

Cancer Immunotherapy in Israel shows long term results and less side effects. (14/12/2017)
Molecular genomic tests for precision cancer treatment in Israel. (03/12/2017)

♦ Precision Medicine, Personalized Medicine and Pharmacogenomics is a future. (11/24/2017)

♦ Opdivo (Nivolumab) – immunotherapy against cancer, continues to show good results and recommended by Israeli oncologists for adjuvant therapy and treatment of metastatic melanoma and lung cancer. (11/06/2017)

Caris Molecular Intelligence – molecular test that defines the drugs effective on the cancer tumor, as well as those that are not effective. The performed at DNA, RNA and protein level for precision cancer treatment. (10/06/2017)

♦ Personalized lung cancer treatment in Israel. (13/09/2017)
Innovative treatment of lymphoblastic leukemia (ALL) in Israel approved by FDA. (18/07/2017)

♦ Personalized breast cancer treatment in Israel. (10/07/2017)

♦ What is a personalized cancer treatment? – Dr. Raanan Berger, Director of the Institute of Oncology. (06/07/2017)

♦ CANscript ™ (MitraBiotech) is a unique diagnostic that helps to select an effective treatment for severe forms of cancer individually for each patient and gives a reliable prognosis of the response to treatment. (04/23/2017)

♦ When experts recommend detailed sequential test.

Researchers of Tel Aviv University discovered mechanism of melanoma spread to other organs and develops chemicals that can stop sickness development.

Bladder Cancer – future local immune therapy.

♦ Can cancer spread even before a tumor develops?


♦ Can cancer be inherited? – Genetics reply

Call-Center for an appointment at leading doctors of Israel
Should you like to get an opinion of a leading highly specialized Israeli doctor / surgeon on whether you are receiving the right treatment in your country or if there is more advanced treatment, including personalized and targeted therapy, please contact us. We will promptly coordinate an appointment and / or treatment in Israel. 
Viber, WhatsApp, Telegram

+ 972 54 803 45 32
ResultMed provides medical treatment coordination services for international patients.

!מבקרים באתר היקרים, אנא שימו לב

.אנחנו חברה תיירות מרפא. אנו נותנים שרות פרטי לתיירים בלבד

Are you an international patient? Please send your request

Coronavirus COVID-19 – cancer patients are at high risk of infection and complications

New data indicate that patients with active cancer and immunosuppression have an increased risk of coronary virus infection and secondary complications of the viral disease. This data was obtained from experts from China and published in the Lancet Oncology Journal.

Read More

Tazemetostat for the treatment of epithelioid sarcoma was approved by FDA

Tazemetostat - treatment of epithelioid sarcoma in Israel

Tazemetostat has been approved by FDA (US Food and Drug Administration) for the treatment of epithelioid sarcoma as a first-line drug.

Epithelioid sarcoma refers to a rare subtype of soft tissue sarcoma and it can develop in any part of the body, but more often on the extremities. Most often it affects young people. This type has the highest risk of metastasis to the lymph nodes or lungs.

Tazemetostat is an EZH2 methyltransferase inhibitor and it is used to treat metastatic or advanced forms of cancer (grade 3 and 4). This is the first immunotherapy drug to treat epithelioid sarcoma with unique action mechanism. Previous treatment regimens included only surgical treatment, chemotherapy and radiotherapy, which show low effectiveness in the advanced cases.

Tazemetostat has been approved by the FDA accelerated program. Open clinical studies of immunotherapy for epithelioid sarcoma were conducted in 62 patients. They received 800 mg of the drug twice a day. The overall response rate was 15%.

Side effects of treatment may include:

  • pain
  • fatigue
  • nausea
  • poor appetite
  • vomiting
  • constipation.

In some cases, treatment with Tazemostat may increase the risk of secondary malignant tumors.

When this data was discussed by Advisory Committee at FDA, committee members voted unanimously that the treatment benefits outweigh the potential risks. Approving of a new immunotherapy with Tazemetostat gives great promise for patients with epithelioid sarcoma, especially young people.

Source: emed, FDA

Since many studies are being conducted by the United States together with Israel, the immunotherapy drug may already be available in Israel and prescribed by leading oncologists in our country.

Read More

Screening for colorectal cancer – latest recommendation by NCCN

Screening for colorectal cancer by NCCN

New recommendations have been prepared by an international NCCN team and run counter to the popular approach. According to these guidelines, screening tests for colorectal cancer should not be recommended to all adults aged 50-79 years, but should only be performed regularly if there is an increased risk of malignant diseases.

Today, screening tests are generally recommended in most countries for all adults. The age threshold for some groups has recently been lowered to 45 years.

The cumulative malignancy risk for the appointment of screening tests

Oncologists report that cancer screening tests should be recommended with a combined malignancy risk of 3% or more over the next 15 years or with a threshold at which a balance between benefit and damage tends to benefit the screening.

A survey is not recommended if the total risk is less than 3%. To calculate the risk of a malignant tumor over 15 years, you can use the QCancer calculator. The optimal choice in each case requires joint decision-making by the doctor and the patient.

Diagnostic tests with a cumulative risk of 3%

For those, who have a cumulative risk of more than 3% over 15 years specialists team offers diagnostic tests with any of four available approaches:

  • FIT test (fecal immunochemical test) every year
  • FIT test every two years
  • sigmoidoscopy every year
  • colonoscopy every year.

All four examinations led to a decrease of mortality from colorectal cancer and malignancy reduce.

In the case of an individual risk of 3% FIT test every two years has no effect on the occurrence of malignant tumors, unlike FIT test, sigmoidoscopy and colonoscopy every year, which are proven to diagnose the disease in the early stages and may reduce malignancy. In this case, the benefit degree of the patient depends on his individual malignancy risk.

For whom are these new recommendations?

The new guidelines are for men and adults with no prior screening, if there are no symptoms of colon and rectal cancer, with a life expectancy of at least 15 years. The recommendations are based on new data from three randomized trials, which included a one-off sigmoidoscopy. This allowed to draw certain conclusions about the effect of the cumulative malignancy risk.

A malignant risk-based approach is the most appropriate way for screening of malignant diseases that are already used in cases of prostate and lung cancer screening.

NCCN (National Integrated Cancer Control Network) reported that the new guidelines have not yet changed the Association’s recommendations for cancer screening, and  continue to support screening tests for colon and rectal cancer in high-risk adults aged 50- 75 years old.

Read More

Hematologic malignancies can be inherited by first-degree relatives

Family history and hematologic malignancies

According to new data, if patient was diagnosed with hematological malignant tumors, the first-degree relatives have an increased risk of hematological diseases. This study is published in the Blood journal.

Read More

NCCN Guidelines 2019 for small bowel adenorcacinoma

NCCN guildelines for small bowel cancer and SBA

The main treatment for small bowel adenocarcinoma (SBA) is surgery, while the benefits of adjuvant therapy have not yet been proven. This is indicated in the latest clinical guidelines of the National Comprehensive Cancer Network (NCCN 2019).

The occurrence and progression of small bowel cancer
Compared to colorectal cancer, small bowel adenocarcinoma is not so common, and 10 590 new cases of the disease are expected in USA in 2019, including 1590 deaths. But unlike colorectal cancer and other gastrointestinal malignancies, the SBA incidence is only growing with every year.

The predisposition or risk factors for small bowel cancer are:

  • Inflammatory bowel disease
  • Hereditary diseases
    • Adenomatous polyposis
    • Peutz-Jeghers syndrome
    • Lynch syndrome

Oncologists have only a handful of guidelines for small bowel adenocarcinoma. Last year France joined in with its own recommendations, when the medical association published the first-ever clinical guidelines for SBA.

At the same time, Israeli oncologists use the latest American and European technologies for the of the gastrointestinal tract malignancies treatment, including robotic operations and immunotherapy.
Most cases of small bowel cancer develop in:

  • duodenum (52-57%),
  • small intestine (18-29%)
  • ileum (10-13%)
  • non-specific areas of the small intestine (4-14%).

Complications of small bowel cancer
Tumors are usually accompanied by complications, such as the gastrointestinal obstruction or pain in the abdomen. Patients with the SBA as a rule, have a younger age compared with patients with rectum and colorectal cancer.

The classical treatment approach and adjuvant therapy for small bowel adenocarcinoma
Segmental resection is a standard surgical approach, although some tumors may require the duodenum resection, pancreas, or segmental removal of the duodenum. Clinical observations show that removal of eight lymph nodes at least significantly improves the surgery results.

In addition to surgery for local disease, radiation therapy may be important for individual patients with retroperitoneal duodenal adenocarcinoma, but this may acquire complex decision-making procedures. Studies have not yet shown clear benefits with adjuvant chemotherapy, but in some cases, therapy-based on fluoropyrimidine gives good results.

Current trials for malignant tumors of SBA
Selective studies are currently underway and this may shed light on the importance of adjuvant chemotherapy for stage I-III malignant SBA tumors. Now research groups around the world are focusing on small bowel cancer, receiving and analyzing a lot of new data on the effects of taxane family’s drugs.

Surgery is rarely performed to cure in patients with metastatic adenocarcinoma of the small intestine. Most patients receive systemic treatment, including fluoropyrimidine, taxane, or immunosuppressive therapy. Small bowel adenocarcinoma has a unique genetic profile, unlike  colon and rectal cancer, and this serves as the basis for new specialized or immunosuppressive therapy.

Source: Emed, Israel

⇒ Leading Israeli Doctor in Gastroenterology Cancer

Colon Cancer treatment in Israel

Read More

New treatment options for breast cancer brain metastases (BCBM)

Treatment list of of brain metastases at patients with breast cancer (BCBM)

New clinical evidence suggests that patients live much longer even in cases of breast cancer brain metastases (BCBM) due to modern improved diagnostics, new initial treatment options and systemic methods, as well as a reduction in brain radiation exposure during radiotherapy.

Read More

FoundationOne CDx Ovarian Cancer testing checks an effectiveness of Lynparza targeted therapy

Now FoundationOne CDx Ovarian Cancer molecular oncotest is approved as a supplemental testing by the FDA when prescribing Lynparza — Olaparib. This targeted therapy is used as first-line maintenance treatment for metastatic ovarian cancer with BRCA 1/2 mutations.

Read More

Family history of melanoma increases risk of skin cancer by up to 74%

Melanoma and skin cancer treatment at the best Israeli oncologists

If one of first-degree relatives had a family history of melanoma, there is a significant risk of melanoma occurrence and skin malignant diseases in other family members, especially in the arms and legs. This is evidenced by a long-term study of dermatologists in an article published in the journal of the American Academy of Dermatology, new results of long-term study were announced.

Read More

Required genetic tests for all women diagnosed with breast cancer

Required Genetic Tests for Breast Cancer

According to the new recommendations of the American Society of Breast Surgeons (ASBrS), all women diagnosed with breast cancer are recommended to undergo genetic testis. These tests are performed regardless of the genetic mutations risk and heredity, in accordance with criteria approved by National Comprehensive Cancer Network(NCCN). Found mutations in women will directly affect treatment.

Read More

Treatment for various BRAF melanoma mutations

Therapy with BRAF melanoma mutations – V600E and V600K

Molecular genetic tests allows to determine differences in BRAF gene mutations. It defines the treatment effectiveness for melanoma. New study revealed that there are differences between the BRAF genotypes in melanoma mutation – V600K and V600E. It leads to different responses for targeted therapy and immunotherapy.

Read More

Atezolizumab as a first line treatment for triple negative breast cancer

Atezolizumab immunotherapy for triple negative brest cancer

FDA approved under an accelerated program using Atezolizumab (Tecentriq) and Nab-Paclitaxel (a combination of immunotherapy with chemotherapy). This combination, as the first-line treatment, increases the overall survival in patients with triple negative breast cancer (TNBC). In fact, it is the first immunotherapy approved for this diagnosis.

Read More

Summary – the latest achievements and successful cancer treatment strategies in Israel and the world in 2018

New medicine 2019

2018 has shown progress in treatment of five rare complex oncological diseases. These year achievements were reported in the annual Journal Clinical Cancer Advances, the print publication of the American Society of Clinical Oncology (ASCO), as well as in the Journal of Clinical Oncology in January 2019.

Read More

mFOLFIRINOX – significant survival increase in pancreatic carcinoma treatment

In the new study, the combined treatment of Folfirinox or modified Folfirinox (mFOLFIRINOX) showed impressive results of patients survival with non-metastatic adenocarcinoma of the pancreatic duct (PDAC) after surgical resection, with good performance status.

Read More

Myths and truth about the occurrence of breast cancer (BC)

Breast cancer myth

Nowadays on the Internet there are many myths about breast cancer, why it occurs and what provokes it. Below are the most frequently asked questions.

Read More

Breast cancer: 3 important findings to prevent metastases

facts about breast cancer

The breast cancer disease takes second place on world statistics, and it is dangerous not only by the occurrence rates, but also further development of metastases. New research in comprehensive cancer studying was initiated in Lineberger Center at University Northern Carolina. In this research was found genetic key with an explanation how breast cancer appear and spread.

The Journal of Clinical Investigation published the analysis of scientific geneticists who studied a difference between primary, diagnosed for the first time breast cancer and its metastases. The understanding of development of secondary cancer as researchers consider, will allow to explain cancer emergence. Insight into an essence of these processes opens new opportunities for oncologists on treatment and prevent to develop a metastatic breast cancer.

Read More